ChartRow logo
Data provided bySource: Twelve Data
GH
$143.28-0.52%
as of close, Nov 17, 2026
☾ AH $143.28 -0.52%
Share this page

GH — Guardant Health Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in GH be worth today? →
GH returns: By year · By month · By week · Trailing

Price data

Price
$143.28
YTD price return
+40.28%
YTD total return
+40.28%
Market cap
19.4B
Enterprise value
20B
Shares outstanding
135.3M
52W low
$74.55
52W high
$191.05
From 52W high
-25.00%
From 52W low
+92.19%
52W range
59%$74.55–$191
Beta
1.57

Volume

Rel volume
0.94×
30D volume
2.1M
30D $ vol
337.1M

Insider trading

Insider net 1W
−$28K
Insider net 1M
−$28K
Insider net 3M
−$9.7M
Insider net 1Y
−$129.2M

Form 4 transactions by trade date, as filed; latest on file 2026-11-16.

Fundamentals

Sales (ttm)
1.3B
Sales/share
$9.45
EPS (ttm)
-$3.68
FCF (ttm)
-232.1M
FCF/share
-$1.72
Book value/share
-$2.04
Net margin
-37.93%
ROA
-25.72%
Current ratio
3.60

Growth (CAGR, ttm) · 10Y

Sales
+41.73%+33.63%+30.05%+49.58%
Shares
+7.34%+4.66%+5.88%n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+32.04%+27.68%+22.82%n/a
Price
+48.55%+83.23%+6.35%n/a
Total return
+48.55%+83.23%+6.35%n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-38.9×
Fwd P/E
-547.2×
P/S (ttm)
15.2×
P/B (mrq)
-70.3×
EV/Sales (ttm)
15.7×
FCF yield (ttm)
-1.20%
Buyback yield (realized, 1y)
-7.34%
Shareholder yield (realized, 1y)
-7.34%
Buyback yield (cash, ttm)
-1.33%
Shareholder yield (cash, ttm)
-1.33%

Vs own 10Y history

P/S
50th
P/B
97th

Bar = where today’s multiple sits in GH’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
-0.52%
5D
-7.77%
1M
-9.66%
3M
-11.38%
YTD
+40.28%
1Y
+48.51%
5Y
+36.03%
1D
-0.52%
5D
-7.77%
1M
-9.66%
3M
-11.38%
YTD
+40.28%
1Y
+48.51%
5Y
+36.03%

Fundamentals#

Revenue

5Y CAGR +27.9%5Y CAGR +27.9%YoY +36.1%
$1.3B TTM$361M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m5Y n/mYoY n/m
−$504M TTM−$132.8M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$3.68 TTM−$0.93 Q3 '26
FY19FY20FY21FY22FY23FY24FY25TTM
Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m5Y n/mYoY n/m
−$232.1M TTM−$37.2M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow −$173.5M, capex −$58.7M

Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow −$23.7M, capex −$13.5M

Shares (diluted)

5Y +28.6%5Y +28.6%YoY +7.7%
131.8M TTM134.4M Q3 '26
FY19FY20FY21FY22FY23FY24FY25TTM
Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m5Y n/mYoY n/m
−$485.1M TTM−$124.4M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full GH financials →

Guardant Health, Inc. is a precision oncology company that develops blood- and tissue-based diagnostic tests, data solutions, and analytics for cancer care. Its offerings support multiple stages of the oncology pathway, including screening for colorectal cancer, molecular profiling of tumors, treatment selection, monitoring for residual disease and recurrence, and research into tumor biology and therapeutic response. Products such as Guardant360, Guardant Reveal, Guardant360 Tissue, and Shield provide clinicians and researchers with genomic, epigenomic, transcriptomic, and circulating tumor DNA insights. The company also serves biopharmaceutical organizations through companion diagnostic development, clinical testing services, technology licensing, and real-world data solutions. Its software and data platforms help connect molecular findings with clinical outcomes and relevant research opportunities. Headquartered in Palo Alto, California, Guardant Health, Inc. operates across healthcare, biotechnology, clinical diagnostics, and biopharmaceutical markets, contributing to the broader use of precision medicine in cancer prevention, diagnosis, treatment, and monitoring.

Palo Alto, CA·2,490 employees·Diagnostics & Research·guardanthealth.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding GH#

20 of the 193 ETFs ChartRow carries live hold GH. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
VBKVanguard Small-Cap Growth ETF0.5%
IWPiShares Russell Mid-Cap Growth ETF0.5%
VHTVanguard Health Care ETF0.3%
VXFVanguard Extended Market ETF0.2%
VBVanguard Small-Cap ETF0.2%
IWRiShares Russell Midcap ETF0.1%
VONGVanguard Russell 1000 Growth ETF0.1%
IWFiShares Russell 1000 Growth ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%